An <i>in vivo</i> AD model was established in thrombomodulin (TM)-mutant ApoE<sup>-/-</sup> mice, which display impaired TM-dependent PC activation, and exogenous PC was administered to evaluate its therapeutic effect. This evidence concerns the gene APOE and Alzheimer disease.